Sanofi stock price

Sanofi latest news:


  • 09/20/2017 05:39:06

    UPDATE: Alnylam shares jump 24% on positive results from late-stage trial of hATTR amyloidosis treatment

    Sanofi and Alnylam Pharmaceuticals Inc. on Wednesday reported positive results in a late-stage trial of a treatment for Hereditary ATTR (hATTR) Amyliodosis patients with polyneuropathy. Alnylam shares jumped 24% after resuming trading following a halt. In a joint statement, the companies said an investigational RNAi therapeutic met its primary and secondary endpoints. The disease is an inherited one that is progressively debilitating and often fatal and is caused by mutations in the TTR gene. TTR protein is produced in the liver and usually acts as a carrier for vitamin A. Mutations can cause proteins to accumulate and damage organs and tissue, including the heart. About 50,000 people worldwide suffer from the disease, which currently has no approved treatment apart from liver transplant. Patients typically have a life expectancy of 2.5 to 15 years after the first symptoms appear. "This is a significant milestone that supports our belief that RNAi therapeutics have the potential to become an innovative new class of medicines for patients with rare genetic diseases," said Elias Zerhouni, M.D., president, global R&D at Sanofi in a statement. Alnylam shares had gained 100.4% in 2017 through Tuesday, while the S&P 500 has gained 12%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 09/11/2017 11:08:13

    UPDATE 2-Regeneron, Sanofi asthma drug data fails to excite investors

    PARIS, Sept 11 (Reuters) - Shares of Regeneron Inc and Sanofi SA slid on Monday after late-stage trial data for their asthma drug, dupilumab, fell short of investor expectations.

  • 09/10/2017 23:15:57

    BRIEF-Regeneron, Sanofi announce positive Dupilumab topline results from phase 3 trial in uncontrolled persistent Asthma

    Regeneron Pharmaceuticals Inc(REGN). * Regeneron and Sanofi announce positive Dupilumab topline results from phase 3 trial in uncontrolled persistent Asthma. * Regeneron and Sanofi announce positive Dupilumab topline results from phase 3 trial in uncontrolled persistent Asthma. * Co, Sanofi announced pivotal phase 3 liberty asthma quest study of met its two primary endpoints.

  • 08/17/2017 10:59:47

    Reps. Cummings, Welch to launch investigation into multiple sclerosis drug prices

    Rep. Elijah Cummings (D-Md.) and Rep. Peter Welch (D-Vt.) said Thursday morning that they are launching an investigation into multiple sclerosis drug prices, and have sent letters to seven pharmaceutical companies about their pricing strategies. Letters were sent to Bayer AG , Biogen Inc. , Merck & Co.'s EMD Serono, Novartis AG , Sanofi SA , Teva Pharmaceutical Industries Ltd. and Roche Holding AG . Biogen shares declined 2.9% in heavy midday trade and Teva shares declined 1.1% in moderate trade. The lawmakers asked for information to evaluate multiple sclerosis drugs' "substantial price increases, including information about corporate profits and expenses and documents concerning pricing strategies, patient assistance programs, and drug distribution systems," and requested a response by the end of the month. The average price of a multiple sclerosis disease-modifying therapy rose from $16,000 in 2004 to about $84,000 in 2017, according to the National Multiple Sclerosis Society (the numbers refer to average wholesale price, which does not reflect often-substantial discounts and rebates). Prices for drugs sold by the seven drugmakers have increased by as much as 1,002% since 2012, according to information from the National Multiple Sclerosis Society cited by the two representatives. The lawmakers said that their letter referred to an American Academy of Neurology study that found "some drug companies appear to be increasing their prices and setting new, higher prices in lockstep in competitors," which may reflect a phenomenon called "shadow pricing" in which companies respond to eachothers' price increases. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 08/08/2017 13:37:23

    BRIEF-Sanofi files suit in U.S. to defend patent rights on Lantus

    * Sanofi files suit in the U.S. to defend its patent rights on Lantus

  • 08/01/2017 10:31:19

    BRIEF-Sanofi genzyme says PEI Pharmacare has added Lemtrada to pharmacare formulary

    * Sanofi Genzyme says PEI Pharmacare has added Lemtrada to pharmacare formulary Source text for Eikon: Further company coverage:

  • 07/31/2017 10:04:13

    UPDATE 3-Sanofi raises outlook but key eczema drug disappoints investors

    * Sanofi sees "broadly stable" 2017 earnings (Adds details, comments)

  • 07/31/2017 00:54:34

    Sanofi raises outlook after strong Q2 sales growth

    * Sees "broadly stable" 2017 earnings. * Revenue growth in nearly all divisions but diabetes. * Pleased with Dupixent uptake. * Profits in line with forecast. By Matthias Blamont.

  • 07/26/2017 10:59:54

    GSK gives up on rare diseases as gene therapy gets two customers

    LONDON, July 26 (Reuters) - GlaxoSmithKline is swimming against the tide by getting out of treatments for rare diseases at a time when rivals like Sanofi and Shire see the field as a rich seam for profits.

  • 07/24/2017 12:06:39

    CORRECTED-FDA tentatively approves Merck's copycat of Sanofi's Lantus (July 20)

    July 20 (Reuters) - Merck and Co Inc said on Thursday the U.S. Food and Drug Administration (FDA) tentatively approved its follow-on biologic version of French drugmaker Sanofi SA's blockbuster diabetes treatment, Lantus.

  • 07/20/2017 10:55:27

    FDA tentatively approves Merck's copycat of Sanofi's Lantus

    July 20 (Reuters) - Merck and Co Inc said on Thursday the U.S. Food and Drug Administration (FDA) tentatively approved its biosimilar version of French drugmaker Sanofi SA's blockbuster diabetes treatment, Lantus.

  • More trends:

    Santander Consumer USA Holdings Inc.SC | Santander Holdings USASOV^C | SAP SESAP | Saratoga Investment CorpSAQ | Saratoga Investment CorpSAR | Sasol Ltd.SSL | Saul CentersBFS | Saul CentersBFS^C | Scana CorporationSCG | Schlumberger N.V.SLB |